Publications

1. Zhao J, Zhu S, Nie L, Zhang M, Zheng L, Xu N, Cai D, Sun X, Chen J, Dai J, Ni Y, Wang Z, Zhang X, Liang J, Chen Y, Hu X, Pan X, Yin X, Liu H, Zhao F, Zhang B, Chen H, Miao J, Qin C, Zhao X, Yao J, Liu Z, Liao B, Wei Q, Li X, Liu J, Gao AC, Huang H, Shen PF, Chen N, Zeng H, Sun G. Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate. Cancer Res. 2023 Oct 17 [Epub ahead of print]
   View PubMed
2. Sun R, Yan B, Li H, Ding D, Wang L, Pang J, Ye D, Huang H. Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis. Cancer Res. 2023 Oct 2; 83 (19):3192-3204
   View PubMed
3. Santasusagna S, Zhu S, Jawalagatti V, Carceles-Cordon M, Ertel A, Garcia-Longarte S, Song WM, Fujiwara N, Li P, Mendizabal I, Petrylak DP, Kelly WK, Reddy EP, Wang L, Schiewer MJ, Lujambio A, Karnes J, Knudsen KE, Cordon-Cardo C, Dong H, Huang H, Carracedo A, Hoshida Y, Rodriguez-Bravo V, Domingo-Domenech J. Master transcription factor reprograming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer. Cancer Discov. 2023 Sep 7 Epub 2023 Sept 07
   View PubMed
4. Cavalcante L, Deshmukh SK, Ribeiro JR, Carneiro BA, Dizon DS, Angara K, Mattox T, Wu S, Xiu J, Walker P, Oberley M, Nabhan C, Huang H, Antonarakis ES. Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers. JCO Precis Oncol. 2023 Sep; 7:e2300088
   View PubMed
5. Zhang J, Wei J, Sun R, Sheng H, Yin K, Pan Y, Jimenez R, Chen S, Cui XL, Zou Z, Yue Z, Emch MJ, Hawse JR, Wang L, He HH, Xia S, Han B, He C, Huang H. A lncRNA from the FTO locus acts as a suppressor of the m(6)A writer complex and p53 tumor suppression signaling. Mol Cell. 2023 Aug 3; 83 (15):2692-2708.e7 Epub 2023 July 20
   View PubMed
6. Ding D, Blee AM, Zhang J, Pan Y, Becker NA, Maher LJ 3rd, Jimenez R, Wang L, Huang H. Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis. Nat Commun. 2023 Aug 3; 14 (1):4671 Epub 2023 Aug 03
   View PubMed
7. Ma J, Zhou Y, Pan P, Yu H, Wang Z, Li LL, Wang B, Yan Y, Pan Y, Ye Q, Liu T, Feng X, Xu S, Wang K, Wang X, Jian Y, Ma B, Fan Y, Gao Y, Huang H, Li L. TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks. Nat Commun. 2023 Mar 31; 14 (1):1810
   View PubMed
8. Huang Z, Li X, Tang B, Li H, Zhang J, Sun R, Ma J, Pan Y, Yan B, Zhou Y, Ding D, Yan Y, Jimenez R, Orme JJ, Jin X, Yang J, Huang H, Jia Z. SETDB1 Modulates Degradation of Phosphorylated RB and Anticancer Efficacy of CDK4/6 Inhibitors. Cancer Res. 2023 Mar 15; 83 (6):875-889
   View PubMed
9. Orme JJ, Mer G, Huang H. Hidden tricks in MATH: Hypermorphic mutations in SPOP tumor suppressor explained by cryo-EM. Mol Cell 2023 Mar 2; 83 (5):655-656
   View PubMed
10. Dhital B, Santasusagna S, Kirthika P, Xu M, Li P, Carceles-Cordon M, Soni RK, Li Z, Hendrickson RC, Schiewer MJ, Kelly WK, Sternberg CN, Luo J, Lujambio A, Cordon-Cardo C, Alvarez-Fernandez M, Malumbres M, Huang H, Ertel A, Domingo-Domenech J, Rodriguez-Bravo V. Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer. Cell Rep Med. 2023 Feb 21; 4 (2):100937 Epub 2023 Feb 13
    View PubMed
11. Zhang H, Jin X, Huang H. Deregulation of SPOP in Cancer. Cancer Res. 2023 Feb 15; 83 (4):489-499
    View PubMed
12. Ding D, Zheng R, Tian Y, Jimenez R, Hou X, Weroha SJ, Wang L, Shi L, Huang H. Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer. Nat Commun. 2022 Oct 23; 13 (1):6311
    View PubMed
13. Sun R, Wei T, Ding D, Zhang J, Chen S, He HH, Wang L, Huang H. CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2022 Sep 27; 119 (39):e2205509119 Epub 2022 Sept 21
    View PubMed
14. He Y, Xu W, Xiao YT, Huang H, Gu D, Ren S. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther. 2022 Jun 24; 7 (1):198 Epub 2022 June 24
    View PubMed
15. Zhao J, Sun G, Zhu S, Dai J, Chen J, Zhang M, Ni Y, Zhang H, Shen P, Zhao X, Zhang B, Pan X, Nie L, Yin X, Liang J, Zhang X, Wang Z, Zhu X, Liao B, Liu Z, Armstrong CM, Gao AC, Huang H, Chen N, Zeng H. Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate. BJU Int. 2022 Mar; 129 (3):345-355 Epub 2021 Aug 03
    View PubMed
16. Aspros KGM, Carter JM, Hoskin TL, Suman VJ, Subramaniam M, Emch MJ, Ye Z, Sun Z, Sinnwell JP, Thompson KJ, Tang X, Rodman EPB, Wang X, Nelson AW, Chernukhin I, Hamdan FH, Bruinsma ES, Carroll JS, Fernandez-Zapico ME, Johnsen SA, Kalari KR, Huang H, Leon-Ferre RA, Couch FJ, Ingle JN, Goetz MP, Hawse JR. Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFkappaB/p65 signaling in triple negative breast cancer. NPJ Breast Cancer. 2022 Feb 17; 8 (1):20
    View PubMed
17. Yan Y, Shao J, Ding D, Pan Y, Tran P, Yan W, Wang Z, Li HY, Huang H. 3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O'PROTAC. Chem Commun (Camb). 2022 Feb 15; 58 (14):2383-2386
    View PubMed
18. Burleson M, Deng JJ, Qin T, Duong TM, Yan Y, Gu X, Das D, Easley A, Liss MA, Yew PR, Bedolla R, Kumar AP, Huang TH, Zou Y, Chen Y, Chen CL, Huang H, Sun LZ, Boyer TG. GLI3 Is Stabilized by SPOP Mutations and Promotes Castration Resistance via Functional Cooperation with Androgen Receptor in Prostate Cancer. Mol Cancer Res. 2022 Jan; 20 (1):62-76 Epub 2021 Oct 05
    View PubMed
19. Song C, Zhang J, Liu X, Li M, Wang D, Kang Z, Yu J, Chen J, Pan H, Wang H, Li G, Huang H. PTEN loss promotes Warburg effect and prostate cancer cell growth by inducing FBP1 degradation. Front Oncol. 2022; 12:911466 Epub 2022 Sept 27
    View PubMed
20. Shao J, Yan Y, Ding D, Wang D, He Y, Pan Y, Yan W, Kharbanda A, Li HY, Huang H. Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG. Adv Sci (Weinh). 2021 Oct; 8 (20):e2102555 Epub 2021 Aug 16
    View PubMed
21. Ma J, Shi Q, Cui G, Sheng H, Botuyan MV, Zhou Y, Yan Y, He Y, Wang L, Wang Y, Mer G, Ye D, Wang C, Huang H. SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition. Nat Commun. 2021 Oct 1; 12 (1):5779 Epub 2021 Oct 01
    View PubMed
22. Zhang J, Gao K, Xie H, Wang D, Zhang P, Wei T, Yan Y, Pan Y, Ye W, Chen H, Shi Q, Li Y, Zhao SM, Hou X, Weroha SJ, Wang Y, Zhang J, Karnes RJ, He HH, Wang L, Wang C, Huang H. SPOP mutation induces DNA methylation via stabilizing GLP/G9a. Nat Commun. 2021 Sep 29; 12 (1):5716 Epub 2021 Sept 29
    View PubMed
23. Wu D, Wang L, Huang H. Protocol to apply spike-in ChIP-seq to capture massive histone acetylation in human cells. STAR Protoc. 2021 Sep 17; 2 (3):100681 Epub 2021 July 17
    View PubMed
24. Sun G, Chen J, Liang J, Yin X, Zhang M, Yao J, He N, Armstrong CM, Zheng L, Zhang X, Zhu S, Sun X, Yang X, Zhao W, Liao B, Pan X, Nie L, Yang L, Chen Y, Zhao J, Zhang H, Dai J, Shen Y, Liu J, Huang R, Liu J, Wang Z, Ni Y, Wei Q, Li X, Zhou Q, Huang H, Liu Z, Shen P, Chen N, Zeng H. Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma. Nat Commun. 2021 Sep 6; 12 (1):5262 Epub 2021 Sept 06
    View PubMed
25. Davies A, Nouruzi S, Ganguli D, Namekawa T, Thaper D, Linder S, Karaoglanoglu F, Omur ME, Kim S, Kobelev M, Kumar S, Sivak O, Bostock C, Bishop J, Hoogstraat M, Talal A, Stelloo S, van der Poel H, Bergman AM, Ahmed M, Fazli L, Huang H, Tilley W, Goodrich D, Feng FY, Gleave M, He HH, Hach F, Zwart W, Beltran H, Selth L, Zoubeidi A. An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nat Cell Biol. 2021 Sep; 23 (9):1023-1034 Epub 2021 Sept 06
    View PubMed
26. Huang Z, Tang B, Yang Y, Yang Z, Shi L, Bai Y, Yan B, Karnes RJ, Zhang J, Jimenez R, Wang L, Wei Q, Yang J, Xu W, Jia Z, Huang H. MAP3K7-IKK Inflammatory Signaling Modulates AR Protein Degradation and Prostate Cancer Progression. Cancer Res. 2021 Sep 1; 81 (17):4471-4484 Epub 2021 June 22
    View PubMed
27. He Y, Wang L, Wei T, Xiao YT, Sheng H, Su H, Hollern DP, Zhang X, Ma J, Wen S, Xie H, Yan Y, Pan Y, Hou X, Tang X, Suman VJ, Carter JM, Weinshilboum R, Wang L, Kalari KR, Weroha SJ, Bryce AH, Boughey JC, Dong H, Perou CM, Ye D, Goetz MP, Ren S, Huang H. FOXA1 overexpression suppresses interferon signaling and immune response in cancer. J Clin Invest. 2021 Jul 15; 131(14).
    View PubMed
28. Shi L, Yan Y, He Y, Yan B, Pan Y, Orme JJ, Zhang J, Xu W, Pang J, Huang H. Mutated SPOP E3 Ligase Promotes 17betaHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression. Cancer Res. 2021 Jul 1; 81 (13):3593-3606 Epub 2021 Mar 24
    View PubMed
29. Waddell AR, Huang H, Liao D. CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers. Cancers (Basel). 2021 Jun 8; 13 (12) Epub 2021 June 08
    View PubMed
30. Wang D, Ma J, Botuyan MV, Cui G, Yan Y, Ding D, Zhou Y, Krueger EW, Pei J, Wu X, Wang L, Pei H, McNiven MA, Ye D, Mer G, Huang H. ATM-phosphorylated SPOP contributes to 53BP1 exclusion from chromatin during DNA replication. Sci Adv. 2021 Jun; 7 (25) Epub 2021 June 18
    View PubMed
31. Sun G, Zhang X, Liang J, Pan X, Zhu S, Liu Z, Armstrong CM, Chen J, Lin W, Liao B, Lin T, Huang R, Zhang M, Zheng L, Yin X, Nie L, Shen P, Zhao J, Zhang H, Dai J, Shen Y, Li Z, Liu J, Chen J, Liu J, Wang Z, Zhu X, Ni Y, Qin D, Yang L, Chen Y, Wei Q, Li X, Zhou Q, Huang H, Yao J, Chen N, Zeng H. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma. Clin Cancer Res. 2021 Mar 15; 27 (6):1734-1743 Epub 2021 Jan 07
    View PubMed
32. Zhou Y, Jin X, Ma J, Ding D, Huang Z, Sheng H, Yan Y, Pan Y, Wei T, Wang L, Wu H, Huang H. HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer. Cancer Res. 2021 Mar 15; 81 (6):1486-1499 Epub 2021 Jan 08
    View PubMed
33. He Y, Wei T, Ye Z, Orme JJ, Lin D, Sheng H, Fazli L, Jeffrey Karnes R, Jimenez R, Wang L, Wang L, Gleave ME, Wang Y, Shi L, Huang H. A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. Nat Commun. 2021 Mar 9; 12 (1):1521 Epub 2021 Mar 09
    View PubMed
34. Tang B, Sun R, Wang D, Sheng H, Wei T, Wang L, Zhang J, Ho TH, Yang L, Wei Q, Huang H. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer. Proc Natl Acad Sci U S A. 2021 Feb 23; 118 (8)
    View PubMed
35. Wu D, Yan Y, Wei T, Ye Z, Xiao Y, Pan Y, Orme JJ, Wang D, Wang L, Ren S, Huang H. An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors. Cell Rep. 2021 Feb 16; 34 (7):108744
    View PubMed
36. Wei T, Lu J, Ma T, Huang H, Kocher JP, Wang L. Re-Evaluate Fusion Genes in Prostate Cancer. Cancer Inform. 2021; 20:11769351211027592 Epub 2021 June 21
    View PubMed
37. Wen S, He Y, Wang L, Zhang J, Quan C, Niu Y, Huang H. Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer. Oncogene. 2020 Oct; 39 (42):6556-6571 Epub 2020 Sept 11
    View PubMed
38. Hong Z, Zhang W, Ding D, Huang Z, Yan Y, Cao W, Pan Y, Hou X, Weroha SJ, Karnes RJ, Wang D, Wu Q, Wu D, Huang H. DNA Damage Promotes TMPRSS2-ERG Oncoprotein Destruction and Prostate Cancer Suppression via Signaling Converged by GSK3ß and WEE1. Mol Cell. 2020 Sep 17; 79(6):1008-1023.e4. Epub 2020 Aug 31.
    View PubMed
39. Orme JJ, Huang H. Microenvironment-Mediated Resistance to Anti-Androgen Therapy. Cancer Cell 2020 Aug 10; 38 (2):155-157
    View PubMed
40. Wen S, Niu Y, Huang H. Posttranslational regulation of androgen dependent and independent androgen receptor activities in prostate cancer. Asian J Urol. 2020 Jul; 7 (3):203-218 Epub 2019 Nov 20
    View PubMed
41. Wang B, Zhou Y, Zhang J, Jin X, Wu H, Huang H. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity. Theranostics. 2020; 10 (3):1033-1045 Epub 2020 Jan 01
    View PubMed
42. Shi Q, Zhu Y, Ma J, Chang K, Ding D, Bai Y, Gao K, Zhang P, Mo R, Feng K, Zhao X, Zhang L, Sun H, Jiao D, Chen Y, Sun Y, Zhao SM, Huang H, Li Y, Ren S, Wang C. Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly. Mol Cancer. 2019 Nov 26; 18 (1):170
    View PubMed
43. Yan Y, Ma J, Wang D, Lin D, Pang X, Wang S, Zhao Y, Shi L, Xue H, Pan Y, Zhang J, Wahlestedt C, Giles FJ, Chen Y, Gleave ME, Collins CC, Ye D, Wang Y, Huang H. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer. EMBO Mol Med. 2019 Nov 7; 11 (11):e10659 Epub 2019 Sept 26
    View PubMed
44. Dou L, Yan F, Pang J, Zheng D, Li D, Gao L, Wang L, Xu Y, Shi J, Wang Q, Zhou L, Shen N, Singh P, Wang L, Li Y, Gao Y, Liu T, Chen C, Al-Kali A, Litzow MR, Chi YI, Bode AM, Liu C, Huang H, Liu D, Marcucci G, Liu S, Yu L. Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia. Nat Commun. 2019 Nov 7; 10 (1):5051 Epub 2019 Nov 07
    View PubMed
45. Blee AM, Huang H. Lineage plasticity-mediated therapy resistance in prostate cancer. Asian J Androl. 2019 May-Jun; 21 (3):241-248
    View PubMed
46. Zhao Y, Ding L, Wang D, Ye Z, He Y, Ma L, Zhu R, Pan Y, Wu Q, Pang K, Hou X, Weroha SJ, Han C, Coleman R, Coleman I, Karnes RJ, Zhang J, Nelson PS, Wang L, Huang H. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. EMBO J. 2019 Mar 01; 38(5). Epub 2019 Feb 05.
    View PubMed
47. Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, Ye Z, Ma T, Wu Q, Rodrigues DN, Kohli M, Jimenez R, Wang L, Goodrich DW, de Bono J, Dong H, Wu H, Zhu R, Huang H. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-kappaB Activation and PD-L1 Expression. Mol Cell. 2019 Jan 3; 73 (1):22-35.e6 Epub 2018 Dec 06
    View PubMed
48. Ma L, Yan Y, Bai Y, Yang Y, Pan Y, Gang X, Karnes RJ, Zhang J, Lv Q, Wu Q, Huang H. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer. Theranostics. 2019; 9 (17):5020-5034 Epub 2019 July 09
    View PubMed
49. Bai Y, Yang Y, Yan Y, Zhong J, Blee AM, Pan Y, Ma T, Karnes RJ, Jimenez R, Xu W, Huang H. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis. Theranostics. 2019; 9 (12):3459-3475 Epub 2019 May 24
    View PubMed
50. Yan Y, Huang H. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer. Adv Exp Med Biol. 2019; 1210:319-331
    View PubMed
51. Sheng C, Yao C, Wang Z, Chen H, Zhao Y, Xu D, Huang H, Huang W, Chen S. Cyclophilin J limits inflammation through the blockage of ubiquitin chain sensing. Nat Commun. 2018 Oct 22; 9 (1):4381
    View PubMed
52. Blee AM, He Y, Yang Y, Ye Z, Yan Y, Pan Y, Ma T, Dugdale J, Kuehn E, Kohli M, Jimenez R, Chen Y, Xu W, Wang L, Huang H. TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer. Clin Cancer Res. 2018 Sep 15; 24 (18):4551-4565 Epub 2018 May 29
    View PubMed
53. Jin X, Yan Y, Wang D, Ding D, Ma T, Ye Z, Jimenez R, Wang L, Wu H, Huang H. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4. Mol Cell. 2018 Aug 16; 71 (4):592-605.e4 Epub 2018 July 26
    View PubMed
54. Ye Z, Dong H, Li Y, Ma T, Huang H, Leong HS, Eckel-Passow J, Kocher JA, Liang H, Wang L. Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance. Clin Cancer Res. 2018 Jul 15; 24 (14):3299-3308 Epub 2018 Apr 04
    View PubMed
55. Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, Ma L, Chen J, Yu Z, He Y, Jin X, Pan Y, Ma T, Wang S, Hou X, Weroha SJ, Karnes RJ, Zhang J, Westendorf JJ, Wang L, Chen Y, Xu W, Zhu R, Wang D, Huang H. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer. EMBO Mol Med. 2018 Apr; 10(4).
    View PubMed
56. Ren S, Wei GH, Liu D, Wang L, Hou Y, Zhu S, Peng L, Zhang Q, Cheng Y, Su H, Zhou X, Zhang J, Li F, Zheng H, Zhao Z, Yin C, He Z, Gao X, Zhau HE, Chu CY, Wu JB, Collins C, Volik SV, Bell R, Huang J, Wu K, Xu D, Ye D, Yu Y, Zhu L, Qiao M, Lee HM, Yang Y, Zhu Y, Shi X, Chen R, Wang Y, Xu W, Cheng Y, Xu C, Gao X, Zhou T, Yang B, Hou J, Liu L, Zhang Z, Zhu Y, Qin C, Shao P, Pang J, Chung LWK, Xu J, Wu CL, Zhong W, Xu X, Li Y, Zhang X, Wang J, Yang H, Wang J, Huang H, Sun Y. Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. Eur Urol. 2018 Mar; 73 (3):322-339 Epub 2017 Sept 18
    View PubMed
57. He Y, Lu J, Ye Z, Hao S, Wang L, Kohli M, Tindall DJ, Li B, Zhu R, Wang L, Huang H. Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer. Nucleic Acids Res. 2018 Feb 28; 46 (4):1895-1911
    View PubMed
58. Yang Y, Bai Y, He Y, Zhao Y, Chen J, Ma L, Pan Y, Hinten M, Zhang J, Karnes RJ, Kohli M, Westendorf JJ, Li B, Zhu R, Huang H, Xu W. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2018 Feb 15; 24 (4):834-846 Epub 2017 Nov 22
    View PubMed
59. Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M. A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann Oncol. 2018 Feb 01; 29(2):352-360.
    View PubMed
60. He Y, Zhao Y, Wang L, Bohrer LR, Wang L, Pan Y, Wang L, Huang H. LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation. Oncogene. 2018 Jan 25; 37 (4):534-543 Epub 2017 Oct 09
    View PubMed
61. Yang Y, Blee AM, Wang D, An J, Pan Y, Yan Y, Ma T, He Y, Dugdale J, Hou X, Zhang J, Weroha SJ, Zhu WG, Wang YA, DePinho RA, Xu W, Huang H. Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion. Cancer Res. 2017 Dec 01; 77(23):6524-6537. Epub 2017 Oct 06.
    View PubMed
62. Ding D, Jiang W, Yu W, Zhu H, Liu J, Saiyin H, Wu J, Huang H, Jiang S, Yu L. Reticulocalbin-2 enhances hepatocellular carcinoma proliferation via modulating the EGFR-ERK pathway. Oncogene. 2017 Nov 30; 36 (48):6691-6700 Epub 2017 July 24
    View PubMed
63. Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye Z, Wang S, Pan CW, Zhu Y, Yan Y, Yang Y, Wu D, He Y, Zhang J, Lu D, Liu X, Yu L, Zhao S, Li Y, Lin D, Wang Y, Wang L, Chen Y, Sun Y, Wang C, Huang H. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med. 2017 Sep; 23 (9):1055-1062 Epub 2017 Aug 14
    View PubMed
64. Jin X, Pan Y, Wang L, Ma T, Zhang L, Tang AH, Billadeau DD, Wu H, Huang H. Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction. Cancer Res. 2017 Aug 15; 77 (16):4328-4341 Epub 2017 July 18
    View PubMed
65. Kohli M, Ho Y, Hillman DW, Van Etten JL, Henzler C, Yang R, Sperger JM, Li Y, Tseng E, Hon T, Clark T, Tan W, Carlson RE, Wang L, Sicotte H, Thai H, Jimenez R, Huang H, Vedell PT, Eckloff BW, Quevedo JF, Pitot HC, Costello BA, Jen J, Wieben ED, Silverstein KAT, Lang JM, Wang L, Dehm SM. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. Clin Cancer Res. 2017 Aug 15; 23(16):4704-4715. Epub 2017 May 04.
    View PubMed
66. Fan L, Zhu Q, Liu L, Zhu C, Huang H, Lu S, Liu P. CXCL13 is androgen-responsive and involved in androgen induced prostate cancer cell migration and invasion. Oncotarget. 2017 Aug 8; 8 (32):53244-53261 Epub 2017 June 07
    View PubMed
67. Pan CW, Jin X, Zhao Y, Pan Y, Yang J, Karnes RJ, Zhang J, Wang L, Huang H. AKT-phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction. EMBO J. 2017 Apr 13; 36 (8):995-1010 Epub 2017 Mar 09
    View PubMed
68. Jin X, Pan Y, Wang L, Zhang L, Ravichandran R, Potts PR, Jiang J, Wu H, Huang H. MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation. Oncogenesis. 2017 Apr 10; 6 (4):e312
    View PubMed
69. Jin X, Wang J, Gao K, Zhang P, Yao L, Tang Y, Tang L, Ma J, Xiao J, Zhang E, Zhu J, Zhang B, Zhao SM, Li Y, Ren S, Huang H, Yu L, Wang C. Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer. PLoS Genet. 2017 Apr; 13 (4):e1006748 Epub 2017 Apr 27
    View PubMed
70. Yang J, Jin X, Yan Y, Shao Y, Pan Y, Roberts LR, Zhang J, Huang H, Jiang J. Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression. Sci Rep. 2017 Mar 6; 7:43864 Epub 2017 Mar 06
    View PubMed
71. Qin T, Barron L, Xia L, Huang H, Villarreal MM, Zwaagstra J, Collins C, Yang J, Zwieb C, Kodali R, Hinck CS, Kim SK, Reddick RL, Shu C, O'Connor-McCourt MD, Hinck AP, Sun LZ. A novel highly potent trivalent TGF-beta receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands. Oncotarget. 2016 Dec 27; 7 (52):86087-86102
    View PubMed
72. Wu D, Liu G, Liu Y, Saiyin H, Wang C, Wei Z, Zen W, Liu D, Chen Q, Zhao Z, Zou L, Huang H, Jiang S, Yu L. Zinc finger protein 191 inhibits hepatocellular carcinoma metastasis through discs large 1-mediated yes-associated protein inactivation. Hepatology. 2016 Oct; 64 (4):1148-62 Epub 2016 Aug 02
    View PubMed
73. Blee AM, Liu S, Wang L, Huang H. BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion. Oncotarget. 2016 Jun 21; 7 (25):38319-38332
    View PubMed
74. Zhao J, Zhao Y, Wang L, Wang L, Zhang J, Karnes RJ, Kohli M, Wang G, Huang H. Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer. Oncotarget. 2016 Jun 21; 7 (25):38551-38565
    View PubMed
75. Blee AM, Huang H. Fat lure: adipocytes attract cancer cells out of the prostate. Transl Cancer Res. 2016 Jun; 5 (Suppl 1):S123-S125
    View PubMed
76. Gao K, Wang C, Jin X, Xiao J, Zhang E, Yang X, Wang D, Huang H, Yu L, Zhang P. RNF12 promotes p53-dependent cell growth suppression and apoptosis by targeting MDM2 for destruction. Cancer Lett. 2016 May 28; 375: (1)133-141.
    View PubMed
77. Zhao Y, Wang L, Ren S, Wang L, Blackburn PR, McNulty MS, Gao X, Qiao M, Vessella RL, Kohli M, Zhang J, Karnes RJ, Tindall DJ, Kim Y, MacLeod R, Ekker SC, Kang T, Sun Y, Huang H. Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer. Cell Rep. 2016 Apr 19; 15 (3):599-610 Epub 2016 Apr 07
    View PubMed
78. Gang X, Yang Y, Zhong J, Jiang K, Pan Y, Karnes RJ, Zhang J, Xu W, Wang G, Huang H. P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth. Oncotarget. 2016 Mar 22; 7 (12):15135-49
    View PubMed
79. Li L, Duan T, Wang X, Zhang RH, Zhang M, Wang S, Wang F, Wu Y, Huang H, Kang T. KCTD12 Regulates Colorectal Cancer Cell Stemness through the ERK Pathway. Sci Rep. 2016 Feb 5; 6:20460 Epub 2016 Feb 05
    View PubMed
80. Wang L, Nie J, Sicotte H, Li Y, Eckel-Passow JE, Dasari S, Vedell PT, Barman P, Wang L, Weinshiboum R, Jen J, Huang H, Kohli M, Kocher JP. Measure transcript integrity using RNA-seq data. BMC Bioinformatics. 2016 Feb 3; 17:58 Epub 2016 Feb 03
    View PubMed
81. Wu C, Jin X, Yang J, Yang Y, He Y, Ding L, Pan Y, Chen S, Jiang J, Huang H. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer. Oncotarget. 2016 Jan 19; 7 (3):3440-52
    View PubMed
82. Wu Y, Zhou L, Wang X, Lu J, Zhang R, Liang X, Wang L, Deng W, Zeng YX, Huang H, Kang T. A genome-scale CRISPR-Cas9 screening method for protein stability reveals novel regulators of Cdc25A. Cell Discov. 2016; 2:16014 Epub 2016 May 24
    View PubMed
83. Zhang R, Han J, Daniels D, Huang H, Zhang Z. Detecting the H3F3A mutant allele found in high-grade pediatric glioma by real-time PCR. J Neurooncol. 2016 Jan; 126 (1):27-36 Epub 2015 Sept 16
    View PubMed
84. Zhang P, Zhang Y, Gao K, Wang Y, Jin X, Wei Y, Saiyin H, Wang D, Peng J, Ma J, Tang Y, Wumaier R, Yu H, Dong Y, Huang H, Yu L, Wang C. ASPP1/2-PP1 complexes are required for chromosome segregation and kinetochore-microtubule attachments. Oncotarget. 2015 Dec 8; 6 (39):41550-65
    View PubMed
85. Wang D, Ding L, Wang L, Zhao Y, Sun Z, Karnes RJ, Zhang J, Huang H. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer. Oncotarget. 2015 Dec 1; 6 (38):41045-55
    View PubMed
86. An J, Ren S, Murphy SJ, Dalangood S, Chang C, Pang X, Cui Y, Wang L, Pan Y, Zhang X, Zhu Y, Wang C, Halling GC, Cheng L, Sukov WR, Karnes RJ, Vasmatzis G, Zhang Q, Zhang J, Cheville JC, Yan J, Sun Y, Huang H. Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. Mol Cell. 2015 Sep 17; 59 (6):904-16 Epub 2015 Sept 03
    View PubMed
87. Jiang W, Ding L, Zhu P, Saiyin H, Ji G, Zuo J, Han D, Pan Y, Ding D, Ma X, Zhang Y, Wu J, Yi Q, Liu JO, Huang H, Dang Y, Yu L. Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability. Oncogene. 2015 Aug 20; 34 (34):4460-70 Epub 2014 Nov 17
    View PubMed
88. Gang X, Wang G, Huang H. Androgens regulate SMAD ubiquitination regulatory factor-1 expression and prostate cancer cell invasion. Prostate. 2015 May; 75 (6):561-72 Epub 2015 Jan 28
    View PubMed
89. Pan C, An J, Pan Y, Wang L, Zhang J, Qi J, Huang H. MP55-01 Cytoplasmic FOXO1 Negatively Regulates ERK to Overcome TAXOL Resistance in Prostate Cancer. The Journal of Urology. 2015 April; 193(4).
    
90. Zhang P, Gao K, Jin X, Ma J, Peng J, Wumaier R, Tang Y, Zhang Y, An J, Yan Q, Dong Y, Huang H, Yu L, Wang C. Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-alpha protein turnover. Cell Death Dis. 2015 Mar 12; 6:e1687
    View PubMed
91. Lu J, Lonergan PE, Nacusi LP, Wang L, Schmidt LJ, Sun Z, Van der Steen T, Boorjian SA, Kosari F, Vasmatzis G, Klee GG, Balk SP, Huang H, Wang C, Tindall DJ. The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. J Urol. 2015 Feb; 193 (2):690-8 Epub 2014 Aug 14
    View PubMed
92. Wang L, Huang H, Dougherty G, Zhao Y, Hossain A, Kocher JP. Epidaurus: aggregation and integration analysis of prostate cancer epigenome. Nucleic Acids Res. 2015 Jan; 43 (2):e7 Epub 2014 Nov 05
    View PubMed
93. Wang L, Chen J, Wang C, Uuskula-Reimand L, Chen K, Medina-Rivera A, Young EJ, Zimmermann MT, Yan H, Sun Z, Zhang Y, Wu ST, Huang H, Wilson MD, Kocher JP, Li W. MACE: model based analysis of ChIP-exo. Nucleic Acids Res. 2014 Nov 10; 42 (20):e156 Epub 2014 Sept 23
    View PubMed
94. Wang L, Xiong H, Wu F, Zhang Y, Wang J, Zhang Y, Zhao L, Guo X, Chang LJ, Zhang Y, You MJ, Zhang Y, Koochekpour S, Saleem M, Huang H, Lu J, Deng Y, Lu J. Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth. Cell Rep. 2014 Sep 11; 8 (5):1461-74 Epub 2014 Aug 28
    View PubMed
95. Zhang P, Gao K, Tang Y, Jin X, An J, Yu H, Wang H, Zhang Y, Wang D, Huang H, Yu L, Wang C. Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants. Hum Mutat. 2014 Sep; 35 (9):1142-51 Epub 2014 July 23
    View PubMed
96. Zhang P, Gao K, Tang Y, Jin X, An J, Yu H, Wang H, Zhang Y, Wang D, Huang H, Yu L, Wang C. Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants HumMutat. 2014; 35(9):1142-1151.
    View PubMed
97. Ding L, Chen S, Liu P, Pan Y, Zhong J, Regan KM, Wang L, Yu C, Rizzardi A, Cheng L, Zhang J, Schmechel SC, Cheville JC, Van Deursen J, Tindall DJ, Huang H. CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy. Cancer Res. 2014 Apr 1; 74 (7):2050-61 Epub 2014 Feb 03
    View PubMed
98. Zhao H, Sun Z, Wang J, Huang H, Kocher JP, Wang L. CrossMap: a versatile tool for coordinate conversion between genome assemblies. Bioinformatics. 2014 Apr 1; 30 (7):1006-7 Epub 2013 Dec 18
    View PubMed
99. Zhong J, Ding L, Bohrer LR, Pan Y, Liu P, Zhang J, Sebo TJ, Karnes RJ, Tindall DJ, van Deursen J, Huang H. p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis. Cancer Res. 2014 Mar 15; 74 (6):1870-1880 Epub 2014 Jan 30
    View PubMed
100. An J, Wang C, Deng Y, Yu L, Huang H. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep. 2014 Feb 27; 6 (4):657-69 Epub 2014 Feb 06
     View PubMed
101. Zhao Y, Tindall DJ, Huang H. Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer. Int J Biol Sci. 2014; 10 (6):614-9 Epub 2014 June 05
     View PubMed
102. Huang H. Scaffold attachment factor B1: an intrinsic inhibitor of androgen receptor downregulated in prostate cancer. Asian J Androl. 2013 Nov; 15 (6):703-4 Epub 2013 Sept 30
     View PubMed
103. van der Steen T, Tindall DJ, Huang H. Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci. 2013 Jul 16; 14 (7):14833-59 Epub 2013 July 16
     View PubMed
104. Bohrer LR, Liu P, Zhong J, Pan Y, Angstman J, Brand LJ, Dehm SM, Huang H. FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants. Prostate. 2013 Jul; 73(10):1017-27. Epub 2013 Feb 06.
     View PubMed
105. Wang L, Zeng X, Chen S, Ding L, Zhong J, Zhao JC, Wang L, Sarver A, Koller A, Zhi J, Ma Y, Yu J, Chen J, Huang H. BRCA1 is a negative modulator of the PRC2 complex. EMBO J. 2013 May 29; 32 (11):1584-97 Epub 2013 Apr 26
     View PubMed
106. Xiao Q, Qu K, Wang C, Kong Y, Liu C, Jiang D, Saiyin H, Jia F, Ni C, Chen T, Zhang Y, Zhang P, Qin W, Sun Q, Wang H, Yi Q, Liu J, Huang H, Yu L. HDGF-related protein-3 is required for anchorage-independent survival and chemoresistance in hepatocellular carcinomas. Gut. 2013 Mar; 62(3):440-51. Epub 2012 Apr 05.
     View PubMed
107. Yang Y, Wang C, Zhang P, Gao K, Wang D, Yu H, Zhang T, Jiang S, Hexige S, Hong Z, Yasui A, Liu JO, Huang H, Yu L. Polycomb group protein PHF1 regulates p53-dependent cell growth arrest and apoptosis. J Biol Chem. 2013 Jan 4; 288 (1):529-39 Epub 2012 Nov 13
     View PubMed
108. Mao J, Yu H, Wang C, Sun L, Jiang W, Zhang P, Xiao Q, Han D, Saiyin H, Zhu J, Chen T, Roberts LR, Huang H, Yu L. Metallothionein MT1M is a tumor suppressor of human hepatocellular carcinomas. Carcinogenesis. 2012 Dec; 33(12):2568-77. Epub 2012 Sep 12.
     View PubMed
109. Jiang J, Pan Y, Regan KM, Wu C, Zhang X, Tindall DJ, Huang H. Androgens repress expression of the F-box protein Skp2 via p107 dependent and independent mechanisms in LNCaP prostate cancer cells. Prostate. 2012 Feb 1; 72(2):225-32. Epub 2011 May 31.
     View PubMed
110. Huang H, Tindall DJ. Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochim Biophys Acta. 2011 Nov; 1813(11):1961-4. Epub 2011 Jan 14.
     View PubMed
111. Lu H, Liu P, Pan Y, Huang H. Inhibition of cyclin-dependent kinase phosphorylation of FOXO1 and prostate cancer cell growth by a peptide derived from FOXO1. Neoplasia. 2011 Sep; 13(9):854-63.
     View PubMed
112. Lu H, Huang H. FOXO1: a potential target for human diseases. Curr Drug Targets. 2011 Aug; 12(9):1235-44.
     View PubMed
113. Zhang H, Pan Y, Zheng L, Choe C, Lindgren B, Jensen ED, Westendorf JJ, Cheng L, Huang H. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res. 2011 May 1; 71(9):3257-67. Epub 2011 Apr 19.
     View PubMed
114. Zeng X, Chen S, Huang H. Phosphorylation of EZH2 by CDK1 and CDK2: a possible regulatory mechanism of transmission of the H3K27me3 epigenetic mark through cell divisions. Cell Cycle. 2011 Feb 15; 10(4):579-83.
     View PubMed
115. Chen S, Bohrer LR, Rai AN, Pan Y, Gan L, Zhou X, Bagchi A, Simon JA, Huang H. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol. 2010 Nov; 12(11):1108-14. Epub 2010 Oct 10.
     View PubMed
116. Bohrer LR, Chen S, Hallstrom TC, Huang H. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer. Endocrinology. 2010 Nov; 151(11):5136-45. Epub 2010 Sep 29.
     View PubMed
117. Jiang J, Huang H. Targeting the Androgen Receptor by Taxol in Castration-Resistant Prostate Cancer. Mol Cell Pharmacol. 2010 Jan 1; 2(1):1-5.
     View PubMed
118. Wang D, Montgomery RB, Schmidt LJ, Mostaghel EA, Huang H, Nelson PS, Tindall DJ. Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression. Cancer Res. 2009 Dec 15; 69 (24):9448-56
     View PubMed
119. Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, Sun Z, Wang Y, Huang H. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res. 2009 Nov 1; 69 (21):8386-94 Epub 2009 Oct 13
     View PubMed
120. Gan L, Liu P, Lu H, Chen S, Yang J, McCarthy JB, Knudsen KE, Huang H. Cyclin D1 promotes anchorage-independent cell survival by inhibiting FOXO-mediated anoikis. Cell Death Differ. 2009 Oct; 16(10):1408-17. Epub 2009 Jul 03.
     View PubMed
121. Liu P, Li S, Gan L, Kao TP, Huang H. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. Cancer Res. 2008 Dec 15; 68(24):10290-9.
     View PubMed
122. Liu P, Kao TP, Huang H. CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor. Oncogene. 2008 Aug 7; 27(34):4733-44. Epub 2008 Apr 14.
     View PubMed
123. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci. 2007 Aug 1; 120(Pt 15):2479-87.
     View PubMed
124. Huang H, Tindall DJ. CDK2 and FOXO1: a fork in the road for cell fate decisions. Cell Cycle. 2007 Apr 15; 6(8):902-6. Epub 2007 Apr 05.
     View PubMed
125. Huang H, Regan KM, Lou Z, Chen J, Tindall DJ. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science. 2006 Oct 13; 314 (5797):294-7
     View PubMed
126. Huang H, Tindall DJ. FOXO factors: a matter of life and death. Future Oncol. 2006 Feb; 2 (1):83-9
     View PubMed
127. Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, Tindall DJ. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A. 2005 Feb 1; 102 (5):1649-54 Epub 2005 Jan 24
     View PubMed
128. Huang H, Muddiman DC, Tindall DJ. Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells. J Biol Chem. 2004 Apr 2; 279 (14):13866-77 Epub 2004 Jan 15
     View PubMed
129. Huang H, Zegarra-Moro OL, Benson D, Tindall DJ. Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells. Oncogene. 2004 Mar 18; 23(12):2161-76.
     View PubMed
130. Santos AF, Huang H, Tindall DJ. The androgen receptor and its clinical relevance in prostate cancer. Steroid. 2004; 69:79-85.
     
131. Deocampo ND, Huang H, Tindall DJ. The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol. 2003 Jun; 28: (2)145-53.
     View PubMed
132. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 2002 Feb 15; 62(4):1008-13.
     View PubMed
133. Huang H, Tindall DJ. The role of the androgen receptor in prostate cancer. Crit Rev Eukaryot Gene Expr. 2002; 12 (3):193-207
     View PubMed
134. Debes JD, Schmidt LJ, Huang H, Tindall DJ. p300 mediates interleukin-6-dependent transactivation of the androgen receptor. Cancer Research. 2002; 62:5632-5636.
     
135. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst. 2001 Nov 21; 93 (22):1687-97
     View PubMed
136. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology. 2001 Nov; 142 (11):4795-805
     View PubMed
137. Huang H, Cheville JC, Pan Y, Roche PC, Schmidt LJ, Tindall DJ. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem. 2001 Oct 19; 276 (42):38830-6 Epub 2001 Aug 08
     View PubMed
138. Shridhar V, Bible KC, Staub J, Avula R, Lee YK, Kalli K, Huang H, Hartmann LC, Kaufmann SH, Smith DI. Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res. 2001 May 15; 61 (10):4258-65
     View PubMed
139. Zhang JS, Wang L, Huang H, Nelson M, Smith DI. Keratin 23 (K23), a novel acidic keratin, is highly induced by histone deacetylase inhibitors during differentiation of pancreatic cancer cells. Genes Chromosomes Cancer. 2001 Feb; 30(2):123-35.
     View PubMed
140. Huang H, Reed CP, Zhang JS, Shridhar V, Wang L, Smith DI. Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells. Cancer Res. 1999 Jun 15; 59(12):2981-8.
     View PubMed
141. Wang L, Darling J, Wang L, Zhang JS, Zhang JS, Huang H, Liu W, Liu W, Smith DI. Allele-specific late replication and fragility of the most active common fragile site, FRA3B. Hum Mol Genet. 1999 Mar; 8 (3):431-7
     View PubMed
142. Shi Q, Shan X, Zhang J, Zhang X, Chen Y, Deng X, Huang H, Yu L, Zhao S, Zheng Q, Adler I. [A DNA probe suitable for the detection of chromosome 21 copy number in human interphase nuclei by fluorescence in situ hybridization]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 1999 Feb 10; 16(1):36-40.
     View PubMed
143. Huang H, Reed CP, Mordi A, Lomberk G, Wang L, Shridhar V, Hartmann L, Jenkins R, Smith DI. Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer. Genes Chromosomes Cancer. 1999 Jan; 24(1):48-55.
     View PubMed
144. Mai M, Huang H, Reed C, Qian C, Smith JS, Alderete B, Jenkins R, Smith DI, Liu W. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. Genomics. 1998 Aug 1; 51 (3):359-63
     View PubMed
145. Huang H, Qian J, Proffit J, Wilber K, Jenkins R, Smith DI. FRA7G extends over a broad region: coincidence of human endogenous retroviral sequences (HERV-H) and small polydispersed circular DNAs (spcDNA) and fragile sites. Oncogene. 1998 May 7; 16(18):2311-9.
     View PubMed
146. Jenkins RB, Qian J, Lee HK, Huang H, Hirasawa K, Bostwick DG, Proffitt J, Wilber K, Lieber MM, Liu W, Smith DI. A molecular cytogenetic analysis of 7q31 in prostate cancer. Cancer Res. 1998 Feb 15; 58(4):759-66.
     View PubMed
147. Huang H, Qian C, Jenkins RB, Smith DI. Fish mapping of YAC clones at human chromosomal band 7q31.2: identification of YACS spanning FRA7G within the common region of LOH in breast and prostate cancer. Genes Chromosomes Cancer. 1998 Feb; 21 (2):152-9
     View PubMed
148. Smith DI, Huang H, Wang L. Common fragile sites and cancer (review). Int J Oncol. 1998 Jan; 12(1):187-96.
     View PubMed
149. Mai M, Huang H, Reed CP, Qian C, Smith JS, Alderete B, Jenkins RB, Smith DI, Liu W. Genomic organization of p73 and mutation analysis of this gene in oligodendrogliomas with chromosome 1p deletions. Genomics. 1998; 51:359-63.
     
150. Huang H, Zhang X, Chen Y. Chromosomal homologies between Hom sapiens and Macaca mulatta and implications for human chromosome evolution. Acta Zoologica Sinica. 1998; 50:187-196.
     
151. Pan Y, Xue Y, Huang H, Chen Y, Xia X, Guo Y, Xie X, Ran C. The application of chromosome painting technique to study hematological malignancies. Chinese Journal of Medical Genetics. 1997; 14:203-206.
     
152. Pan S, Zhang X, Huang H, Chen Y, Huang G. Study of human, Macaca mulatta, Macaca fasicularis chromosome using fluorescence in situ hybridization (FISH). Hereditas. 1997; 19:9-12.
     
153. Han S, Yu L, Huang H, Xu L, Li X, Zhao S. A new method of isolating YAC DNA used as probe for FISH. High Technology Letters. 1996; 6:38-41.
     
154. Zhang X, Huang H, Chen Y, Pan Y, Xue Y, Guo Y, Xie X, Ran C. Detection of rare ph translocation in chronic myelogenous leukemia by chromosome painting. Chinese Journal of Medical Genetics. 1996; 13:337-340.
     
155. Huang H, Zhang X, Chen Y, Cui Y. [A study on complicated chromosome translocation by fluorescence in situ hybridization (FISH) of G-banded chromosomes]. Yi Chuan Xue Bao. 1996; 23(5):338-42.
     View PubMed
156. Huang H, Zhang X, Xue M, Chen Y, Xu Z, Wang X. A de novo chromosome aberration in uterine leiomyomas detected by fluorescence in situ hybridization. Chinese Journal of Medical Genetics. 1995; 12:237-238.
     
157. Huang H, Zhang X, Chen Y. [Studies of the homology of chromosomes between human being and rhesus monkey with chromosomal in situ suppression hybridization]. Yi Chuan Xue Bao. 1993; 20(3):193-200.
     View PubMed
158. Huang H, Chen Y. Nonradioactive chromosomal in situ hybridization and its applications. Foreign Medicine. 1993; 16:70-75.